CJC-1295 Ipamorelin Blend 10mg – Research Peptide for GH Release Studies

The CJC-1295 Ipamorelin Blend is a highly researched synergistic peptide combination designed for laboratory studies on growth hormone (GH) axis modulation. Combining CJC-1295 (no DAC, Mod GRF 1-29) with Ipamorelin, this blend targets complementary pathways: CJC-1295 provides sustained GHRH receptor stimulation for prolonged GH pulses, while Ipamorelin acts as a selective ghrelin mimetic (GHS-R agonist) for rapid, potent GH release without impacting other pituitary hormones like prolactin or cortisol.

In experimental models, the CJC-1295 Ipamorelin blend has shown potential for amplified natural GH secretion, making it a popular reference compound in endocrine, metabolism, and anti-aging research. Results in studies often include enhanced body composition, improved recovery markers, and better sleep architecture analogs.

Key Research Benefits of CJC-1295 Ipamorelin Blend

• Enhanced GH Pulsatility: Synergistic action may increase GH/IGF-1 levels more effectively than single peptides alone in lab settings.
• Body Composition Studies: Promotes lean muscle development and fat metabolism, particularly targeting visceral and abdominal areas in animal models.
• Muscle Growth & Recovery: Accelerates tissue repair and post-exercise recovery markers in research environments.
• Anti-Aging & Vitality Research: Supports investigations into skin elasticity, hair follicle strength, deeper sleep patterns, and overall regenerative processes.
• Metabolic & Sleep Studies: Potential for improved insulin sensitivity, energy levels, and restorative sleep in controlled experiments.

How CJC-1295 Ipamorelin Works in Research

CJC-1295 (no DAC) extends GH release duration via GHRH pathway activation, while Ipamorelin delivers a sharp, selective pulse via GHS-R1a. This dual mechanism mimics natural GH secretion patterns more closely than single agents, reducing potential desensitization in long-term studies. Common observations include mild injection-site responses in models, with noticeable effects emerging in 2–4 weeks of simulated protocols.

Product Specifications

• Form: Lyophilized powder (reconstitute for research use)
• Purity: >99% (third-party tested)
• Blend: CJC-1295 (no DAC) + Ipamorelin (typically 5mg/5mg or 10mg total)
• Intended for: In vitro and laboratory research only

Back to Peptide Basics Home | Explore related research compounds: Ipamorelin Single | CJC-1295 No DAC (links assumed; update with actual URLs if available).